» Articles » PMID: 30600678

Tumor Necrosis Factor Alpha-308G/A Polymorphism and the Risk of Multiple Myeloma: A Meta-Analysis of Pooled Data from Twelve Case-Control Studies

Overview
Journal Turk J Haematol
Specialty Hematology
Date 2019 Jan 3
PMID 30600678
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Tumor necrosis factor alpha (TNF-α) is an important cytokine involved in inflammation, immune response, and other biological processes. The association between polymorphism -308G/A in its promoter and the risk of multiple myeloma (MM) is not clear. Thus, we conducted a meta-analysis to clarify this question.

Materials And Methods: Twelve eligible studies, which included 2204 MM cases and 3478 controls, were enrolled in our meta-analysis by searching the PubMed, China National Knowledge Infrastructure, Scopus, Web of Science, and Google Scholar databases up to December 2018. The effect of polymorphism -308G/A on MM risk was evaluated by calculating the pooled odds ratio (OR) and the 95% confidence interval (CI). Furthermore, the Q-test and I2 statistical analyses were used to estimate the degree of heterogeneity. Sensitivity analysis was conducted to test the robustness of the meta-analysis results. Publication bias was assessed by Egger’s test and visual inspection of a funnel plot.

Results: In the dominant model, -308G/A polymorphism was associated with reduced MM risk (OR=0.80, 95% CI: 0.65-0.97), and it also demonstrated a significant protective effect with a pooled OR of 0.82 (95% CI: 0.68-0.99) in the Caucasian subgroup. Because of the limited number of individual studies with AA genotype carriers, only eight studies were included in the recessive model, and no significant difference was observed. Moreover, the meta-analysis of the allele frequency demonstrated that the A allele has a protective effect against MM risk with a pooled OR of 0.83 (95% CI: 0.69-0.99). Sensitivity analysis suggested that the synthesized effect size was not influenced by any individual study. Moreover, the Egger’s test statistical analysis suggested that publication bias was not obvious in the present analysis.

Conclusion: Overall, the -308G/A polymorphism was associated with reduced MM risk in the dominant model and allele frequency. Further investigation is needed to gain better insight.

Citing Articles

Polymorphism (rs1143634) and IL-1β Plasma Concentration as Predictors of Nutritional Disorders and Prognostic Factors in Multiple Myeloma Patients.

Mazurek M, Szudy-Szczyrek A, Homa-Mlak I, Hus M, Malecka-Massalska T, Mlak R Cancers (Basel). 2024; 16(7).

PMID: 38610941 PMC: 11011170. DOI: 10.3390/cancers16071263.


Transplantation of autologous bone marrow pre-loaded with oncolytic myxoma virus is efficacious against drug-resistant Vk*MYC mouse myeloma.

Villa N, Rahman M, Mamola J, Sharik M, de Matos A, Kilbourne J Oncotarget. 2022; 13:490-504.

PMID: 35251496 PMC: 8893797. DOI: 10.18632/oncotarget.28205.

References
1.
Abraham L, Kroeger K . Impact of the -308 TNF promoter polymorphism on the transcriptional regulation of the TNF gene: relevance to disease. J Leukoc Biol. 1999; 66(4):562-6. DOI: 10.1002/jlb.66.4.562. View

2.
Zheng C, Huang D, Bergenbrant S, Sundblad A, Osterborg A, Bjorkholm M . Interleukin 6, tumour necrosis factor alpha, interleukin 1beta and interleukin 1 receptor antagonist promoter or coding gene polymorphisms in multiple myeloma. Br J Haematol. 2000; 109(1):39-45. DOI: 10.1046/j.1365-2141.2000.01963.x. View

3.
Kyle R, Therneau T, Rajkumar S, Offord J, Larson D, Plevak M . A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002; 346(8):564-9. DOI: 10.1056/NEJMoa01133202. View

4.
Neben K, Mytilineos J, Moehler T, Preiss A, Kraemer A, Ho A . Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma. Blood. 2002; 100(6):2263-5. View

5.
Jurisic V, Colovic M . Correlation of sera TNF-alpha with percentage of bone marrow plasma cells, LDH, beta2-microglobulin, and clinical stage in multiple myeloma. Med Oncol. 2002; 19(3):133-9. DOI: 10.1385/MO:19:3:133. View